Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
← catalyst calendarNCT06998095 · readout in 1,169 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
210estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-11-28 | estimated | When the study began enrolling |
| Primary completion | 2029-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Severe Asthma
- Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)
Primary outcomes
what the primary-completion date above is the date OFIncidence proportion of AEs, ADRs, SAEs, SADRs, unexpected AEs/ADRs and unexpected SAEs/SADRs
measured Baseline to Week 24 or 30 days after last dose if discontinued earlier.
Characterization of AEs/ADRs (nature, maximum severity, causality to tezepelumab, actions taken, and outcomes)
measured Baseline to Week 24 or 30 days after last dose if discontinued earlier.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed